IKT (Inhibikase Therapeutics) Net Margin % : 0.00% (As of Dec. 2024)

Inhibikase Therapeutics Net Margin % Chart

Inhibikase Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Inhibikase Therapeutics's Net Margin %

For the Biotechnology subindustry, Inhibikase Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibikase Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Inhibikase Therapeutics's Net Margin % falls into.

Inhibikase Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Inhibikase Therapeutics's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Inhibikase Therapeutics's Net Margin for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhibikase Therapeutics  (NAS:IKT) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Inhibikase Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Inhibikase Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibikase Therapeutics Business Description